Across ILUSTRO and the phase 1 study, the concordance rate (overall percentage agreement) of CLDN18.2 positivity between archival and baseline tumor samples was 61.1% (22/36) (Supplementary Table S4). Here, CLDN18 is linked to neoplasm.